Gilead Sciences Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Dan O'Day
Chief executive officer
US$21.6m
Total compensation
CEO salary percentage | 7.8% |
CEO tenure | 5yrs |
CEO ownership | 0.04% |
Management average tenure | 4.1yrs |
Board average tenure | 6.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | US$6b |
Sep 30 2023 | n/a | n/a | US$6b |
Jun 30 2023 | n/a | n/a | US$5b |
Mar 31 2023 | n/a | n/a | US$6b |
Dec 31 2022 | US$22m | US$2m | US$5b |
Sep 30 2022 | n/a | n/a | US$3b |
Jun 30 2022 | n/a | n/a | US$4b |
Mar 31 2022 | n/a | n/a | US$5b |
Dec 31 2021 | US$19m | US$2m | US$6b |
Sep 30 2021 | n/a | n/a | US$7b |
Jun 30 2021 | n/a | n/a | US$5b |
Mar 31 2021 | n/a | n/a | US$301m |
Dec 31 2020 | US$19m | US$2m | US$123m |
Sep 30 2020 | n/a | n/a | US$1b |
Jun 30 2020 | n/a | n/a | -US$257m |
Mar 31 2020 | n/a | n/a | US$5b |
Dec 31 2019 | US$29m | US$1m | US$5b |
Compensation vs Market: Dan's total compensation ($USD21.62M) is above average for companies of similar size in the AR market ($USD5.56M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan O'Day (59 yo)
5yrs
Tenure
US$21,621,253
Compensation
Mr. Daniel P. O'Day, also known as Dan, serves as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019. He served as Member of Supervisory Board at Galapagos NV since October 22,...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 5yrs | US$21.62m | 0.039% $ 30.1b | |
Executive VP & CFO | 4.3yrs | US$8.40m | 0.011% $ 8.4b | |
Executive VP of Corporate Affairs | 1.6yrs | US$4.82m | 0.0011% $ 850.5m | |
Chief Commercial Officer | 4.7yrs | US$9.24m | 0.0095% $ 7.4b | |
Chief Medical Officer | 4.3yrs | US$9.04m | 0.0079% $ 6.1b | |
Senior VP | less than a year | no data | 0.0026% $ 2.0b | |
Vice President of Investor Relations | 3.2yrs | no data | no data | |
Executive Vice President of Human Resources | 4.6yrs | no data | no data | |
Senior Vice President of Research | 4.1yrs | no data | no data | |
Senior Vice President of Commercial Operations of Australia | no data | no data | no data | |
Executive Vice President of Research | 2.9yrs | no data | no data | |
Senior Vice President & Therapeutic Area Head of Gilead Oncology | 2.7yrs | no data | no data |
4.1yrs
Average Tenure
57yo
Average Age
Experienced Management: GILD's management team is considered experienced (4.1 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 5yrs | US$21.62m | 0.039% $ 30.1b | |
Independent Director | 3.4yrs | US$429.93k | 0.00064% $ 494.8m | |
Member of Scientific Advisory Board | no data | US$16.00k | no data | |
Independent Director | 6.2yrs | US$414.88k | 0.0018% $ 1.4b | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Lead Independent Director | 14.7yrs | US$489.93k | 0.0074% $ 5.8b | |
Independent Director | 7.6yrs | US$434.93k | 0.00011% $ 85.0m | |
Chairperson of Scientific Advisory Board | no data | no data | no data |
6.2yrs
Average Tenure
68yo
Average Age
Experienced Board: GILD's board of directors are considered experienced (6.2 years average tenure).